Current and Future Medical Therapies for Adenomyosis

K H Tsui, 2014, Medical treatment for adenomyosis and/or adenomyoma, Taiwan J Obstet Gynecol, 53, 459, 10.1016/j.tjog.2014.04.024

J M Higham, 1990, Assessment of menstrual blood loss using a pictorial chart, Br J Obstet Gynaecol, 97, 734, 10.1111/j.1471-0528.1990.tb16249.x

D A Ruta, 1995, Assessment of patients with menorrhagia: how valid is a structured clinical history as a measure of health status?, Qual Life Res, 4, 33, 10.1007/BF00434381

R Melzack, 1987, The short-form McGill Pain Questionnaire, Pain, 30, 191, 10.1016/0304-3959(87)91074-8

R Rosen, 2000, The female sexual function index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function, J Sex Marital Ther, 26, 191, 10.1080/009262300278597

J B Spies, 2002, The UFS-QOL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata, Obstet Gynecol, 99, 290

C Jenkinson, 2008, Evaluation of the American version of the 30-item Endometriosis Health Profile (EHP-30), Qual Life Res, 17, 1147, 10.1007/s11136-008-9403-9

A Yamanaka, 2014, Progesterone and synthetic progestin, dienogest, induce apoptosis of human primary cultures of adenomyotic stromal cells, Eur J Obstet Gynecol Reprod Biol, 179, 170, 10.1016/j.ejogrb.2014.05.031

O M Shaaban, 2015, Levonorgestrel-releasing intrauterine system versus a low-dose combined oral contraceptive for treatment of adenomyotic uteri: a randomized clinical trial, Contraception, 92, 301, 10.1016/j.contraception.2015.05.015

S Cho, 2008, Clinical effects of the levonorgestrel-releasing intrauterine device in patients with adenomyosis, Am J Obstet Gynecol, 198, 373.e1, 10.1016/j.ajog.2007.10.798

L Fedele, 1997, Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device, Fertil Steril, 68, 426, 10.1016/S0015-0282(97)00245-8

S Kelekci, 2012, Effects of levonorgestrel-releasing intrauterine system and T380A intrauterine copper device on dysmenorrhea and days of bleeding in women with and without adenomyosis, Contraception, 86, 458, 10.1016/j.contraception.2012.04.001

L Li, 2019, Treatment of symptomatic adenomyosis with the levonorgestrel-releasing intrauterine system, Int J Gynaecol Obstet, 146, 357, 10.1002/ijgo.12887

D S Park, 2015, Clinical experiences of the levonorgestrel-releasing intrauterine system in patients with large symptomatic adenomyosis, Taiwan J Obstet Gynecol, 54, 412, 10.1016/j.tjog.2014.05.009

O Ozdegirmenci, 2011, Comparison of levonorgestrel intrauterine system versus hysterectomy on efficacy and quality of life in patients with adenomyosis, Fertil Steril, 95, 497, 10.1016/j.fertnstert.2010.10.009

O Muneyyirci-Delale, 2012, Norethindrone acetate in the medical management of adenomyosis, Pharmaceuticals (Basel), 5, 1120, 10.3390/ph5101120

J Sheng, 2009, The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis, Contraception, 79, 189, 10.1016/j.contraception.2008.11.004

M Fawzy, 2015, Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: a prospective clinical trial, Arch Gynecol Obstet, 292, 1267, 10.1007/s00404-015-3755-5

T Hirata, 2014, Efficacy of dienogest in the treatment of symptomatic adenomyosis: a pilot study, Gynecol Endocrinol, 30, 726, 10.3109/09513590.2014.926882

Y Osuga, 2017, Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind, multicenter, placebo-controlled study, Fertil Steril, 108, 673, 10.1016/j.fertnstert.2017.07.021

J Kitawaki, 1997, Expression of aromatase cytochrome P450 protein and messenger ribonucleic acid in human endometriotic and adenomyotic tissues but not in normal endometrium, Biol Reprod, 57, 514, 10.1095/biolreprod57.3.514

T Yamamoto, 1993, Evidence for estrogen synthesis in adenomyotic tissues, Am J Obstet Gynecol, 169, 734, 10.1016/0002-9378(93)90654-2

A M Badawy, 2012, Aromatase inhibitors or gonadotropin-releasing hormone agonists for the management of uterine adenomyosis: a randomized controlled trial, Acta Obstet Gynecol Scand, 91, 489, 10.1111/j.1600-0412.2012.01350.x

P Bouchard, 2011, Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety, Fertil Steril, 96, 1175, 10.1016/j.fertnstert.2011.08.021

N Chabbert-Buffet, 2005, Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications, Hum Reprod Update, 11, 293, 10.1093/humupd/dmi002

M Gracia, 2018, Ulipristal acetate improves clinical symptoms in women with adenomyosis and uterine myomas, J Minim Invasive Gynecol, 25, 1274, 10.1016/j.jmig.2018.04.002

X Che, 2020, The new application of mifepristone in the relief of adenomyosis-caused dysmenorrhea, Int J Med Sci, 17, 224, 10.7150/ijms.39252

E Mahase, 2020, Uterine fibroid drug is recalled after case of liver failure requiring transplant prompts EU review, BMJ, 368, m1112, 10.1136/bmj.m1112

K N Khan, 2010, Cell proliferation effect of GnRH agonist on pathological lesions of women with endometriosis, adenomyosis and uterine myoma, Hum Reprod, 25, 2878, 10.1093/humrep/deq240

H S Taylor, 2017, Treatment of endometriosis-associated pain with elagolix, an oral GnRH antagonist, N Engl J Med, 377, 28, 10.1056/NEJMoa1700089

O Donnez, 2020, Gonadotropin-releasing hormone antagonist (linzagolix): a new therapy for uterine adenomyosis, Fertil Steril, 114, 640, 10.1016/j.fertnstert.2020.04.017

S Akira, 2009, Efficacy of long-term, low-dose gonadotropin-releasing hormone agonist therapy (draw-back therapy) for adenomyosis, Med Sci Monit, 15, CR1

J L Kang, 2010, Efficacy of gonadotropin-releasing hormone agonist and an extended-interval dosing regimen in the treatment of patients with adenomyosis and endometriosis, Gynecol Obstet Invest, 69, 73, 10.1159/000258683

Q Li, 2018, Drug therapy for adenomyosis: a prospective, nonrandomized, parallel-controlled study, J Int Med Res, 46, 1855, 10.1177/0300060517752997

S Guo, 2018, GnRH agonist improves pregnancy outcome in mice with induced adenomyosis by restoring endometrial receptivity, Drug Des Devel Ther, 12, 1621, 10.2147/DDDT.S162541

B Stoelinga, 2014, Real-time elastography for assessment of uterine disorders, Ultrasound Obstet Gynecol, 43, 218, 10.1002/uog.12519

M Xie, 2019, Elasticity of adenomyosis is increased after GnRHa therapy and is associated with spontaneous pregnancy in infertile patents, J Gynecol Obstet Hum Reprod, 48, 849, 10.1016/j.jogoh.2019.05.003

B Gellersen, 1991, Decidual-type prolactin expression by the human myometrium, Endocrinology, 129, 158, 10.1210/endo-129-1-158

M Lupicka, 2019, Effect of ovarian steroids on vascular endothelial growth factor A expression in bovine uterine endothelial cells during adenomyosis, BMC Vet Res, 15, 473, 10.1186/s12917-019-2222-0

T Mori, 1991, Animal model of uterine adenomyosis: is prolactin a potent inducer of adenomyosis in mice?, Am J Obstet Gynecol, 165, 232, 10.1016/0002-9378(91)90258-S

T Singtripop, 1991, Development of uterine adenomyosis after treatment with dopamine antagonists in mice, Life Sci, 49, 201, 10.1016/0024-3205(91)90004-U

T Singtripop, 1993, Age-related changes in gonadotropin, prolactin and growth hormone levels with reference to the development of uterine adenomyosis in female SHN mice, In Vivo, 7, 147

E A Stewart, 1995, The myometrium of postmenopausal women produces prolactin in response to human chorionic gonadotropin and alpha-subunit in vitro, Fertil Steril, 64, 972, 10.1016/S0015-0282(16)57912-6

M Yamashita, 1997, Increased expression of prolactin receptor mRNA in adenomyotic uterus in mice, Life Sci, 60, 1437, 10.1016/S0024-3205(96)00649-2

O A Kletzky, 1989, Effectiveness of vaginal bromocriptine in treating women with hyperprolactinemia, Fertil Steril, 51, 269, 10.1016/S0015-0282(16)60489-2

M Vermesh, 1988, Vaginal bromocriptine: pharmacology and effect on serum prolactin in normal women, Obstet Gynecol, 72, 693

J K Andersson, 2019, Vaginal bromocriptine improves pain, menstrual bleeding and quality of life in women with adenomyosis: a pilot study, Acta Obstet Gynecol Scand, 98, 1341, 10.1111/aogs.13632

S Mechsner, 2010, Possible roles of oxytocin receptor and vasopressin-1α receptor in the pathomechanism of dysperistalsis and dysmenorrhea in patients with adenomyosis uteri, Fertil Steril, 94, 2541, 10.1016/j.fertnstert.2010.03.015

S W Guo, 2013, Dysmenorrhea and its severity are associated with increased uterine contractility and overexpression of oxytocin receptor (OTR) in women with symptomatic adenomyosis, Fertil Steril, 99, 231, 10.1016/j.fertnstert.2012.08.038

J Nie, 2010, Immunoreactivity of oxytocin receptor and transient receptor potential vanilloid type 1 and its correlation with dysmenorrhea in adenomyosis, Am J Obstet Gynecol, 202, e341

K M Mahar, 2018, Single- and multiple-day dosing studies to investigate high-dose pharmacokinetics of epelsiban and its metabolite, GSK2395448, in healthy female volunteers, Clin Pharmacol Drug Dev, 7, 33, 10.1002/cpdd.363

D Wu, 2014, Clinical efficacy of add-back therapy in treatment of endometriosis: a meta-analysis, Arch Gynecol Obstet, 290, 513, 10.1007/s00404-014-3230-8